Chikungunya Fever Market Research Report – Global Forecast till 2023

Chikungunya Fever Market Research Report – Global Forecast till 2023

ID: MRFR/HC/3273-HCRR | November, 2018 | Region: Global | 90 pages | Half-Cooked Research Reports

Chikungunya Fever Market Research Report: By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests), Treatment (Allopathy, Homeopathy), End User (Hospitals And Clinics, Academic Institutes, Research Laboratories) - Global Forecast till 2023 


Market Scenario:


Chikungunya is a mosquito borne viral disease caused by the RNA virus belonging to the alphavirus genus of family Togaviridae. Chikungunya fever has been reported in more than 60 countries of Asia, Africa, Europe and the Americas. Its transmission from human to human is facilitated by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. Currently, there is no cure for the disease and the treatments are focussed only to relieve the symptoms. In 2016, according to the World Health Organisation, 349 936 suspected and 146 914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported the most cases were Brazil (265 000 suspected cases), Bolivia and Colombia (19 000 suspected cases, respectively).


Increasing per capita healthcare expenditures, rising R&D investments by the market players, and growing geriatric population are the major factors that will drive the market growth during the forecasted period. Moreover, pouring government investments and favourable policies will fuel the market. However, factors such as lack of awareness and cost of treatment and diagnosis can restrain the market growth during the forecasted period.


The chikungunya fever market is expected to grow at CAGR 5.86% during forecast period. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1:- Chikungunya Fever Market Share, by Region

Chikungunya Fever Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The chikungunya fever market is segmented on the basis of diagnosis, treatment, and end users.


On the basis of diagnosis, the market is segmented into ELISA based assays, serological tests, virological tests, and others. ELISA based assays is future segmented into IgM based ELISA and IgG ELISA.


On the basis of treatment, the market is segmented into allopathy, homeopathy, ayurveda, and others. The allopathy segmented is sub segmented into anti-pyretics, optimal analgesics, and others. The homeopathy segment is sub segmented into pyroginum, rhus-tox, cedron, and others. The ayurveda segment is sub segmented into amrutharista, mahasudarshana churna, dhanvantaram gutika and others.


On the basis of end users, the market is segmented into hospitals and clinics, academic institutes, research laboratories, and others.


 


Regional Analysis


The Americas dominate the chikungunya fever market owing to a well-developed healthcare sector. Apart from this, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in the Americas. Additionally, increasing geriatric population, rising awareness among the people and expanding R&D expenses for the treatment of chikungunya is boosting the market growth. 


Europe holds the second largest market for chikungunya fever, which is followed by Asia Pacific. Availability of funds for research, rising patient population and government support for research & development will drive the market. On 22 September 2017, according to the European Centre for Disease Prevention and Control there were about 102 autochthonous chikungunya cases in Italy. Such trends for chikungunya fever was seen across the region. This is expected to boost the market growth during the forecasted period.


According to the World Health Organisation, the major outbreaks of chikungunya fever are seen in Asia and the Indian subcontinent. This made Asia Pacific the fastest growing region for the market due to the presence of a huge patient population and presence of huge opportunity in the market. Moreover, continuously developing economies like India and China within the region have increasing healthcare expenditures which fuels the market growth. According to the Indian Brand Equity Foundation, per capita healthcare expenditure was estimated to grow at a CAGR of 5 % during 2008-15 and reach USD 68.6 by 2015.


On the other hand, the Middle East & Africa has the least share in the chikungunya market due to the presence of poor economy especially in the African region. A majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology

Chikungunya Fever Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for chikungunya fever market


The key players for the chikungunya market are Quest Diagnostics Incorporated. (U.S.A), Alere. (U.S.A), Genome Diagnostics Pvt. Ltd. (India), altona Diagnostics (Europe), Bio-Rad Laboratories, Inc. (U.S.A), Sanat Products Ltd. (India), Taj Pharmaceuticals Limited. (India), and Etubics Corporation (U.S.A).

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chikungunya Fever Market, by Diagnosis

6.1 Introduction

6.2 ELISA Based Assays

Market Estimates & Forecast, 2017 – 2023

6.2.1 IgM Based ELISA

6.2.2 IgG Based ELISA

6.3 Serological tests

Market Estimates & Forecast, 2017 – 2023

6.4 Virological tests

Market Estimates & Forecast, 2017 – 2023

6.5 Others

Chapter 7. Global Chikungunya Fever Market, by Treatment

7.1 Introduction

7.2 By Allopathy

Market Estimates & Forecast, 2017 – 2023

7.2.1 Anti-pyretics

7.2.2 Optimal Analgesics

7.2.2 Others

7.3 By Homeopathy

Market Estimates & Forecast, 2017 – 2023

7.3.1 Pyroginum

7.3.2 Rhus-Tox

7.3.3 Cedron

7.3.4 Others

7.4 By Ayurveda

Market Estimates & Forecast, 2017 – 2023

7.4.1 Amrutharista

7.4.2 Mahasudarshana Churna

7.4.3 Dhanvantaram Gutika

7.4.3 Others

7.5 Others

Chapter 8 Global Chikungunya Fever Market, by End User

8.1 Introduction

8.2 Hospitals and Clinics

8.2.1 Market Estimates & Forecast, 2017 – 2023

8.3 Academic Institutes

8.3.1 Market Estimates & Forecast, 2017 – 2023

8.4 Research Laboratories

8.4.1 Market Estimates & Forecast, 2017 – 2023

8.4 Others

Chapter 9. Global Chikungunya Fever Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Quest Diagnostics Incorporated.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Alere

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Genome Diagnostics Pvt. Ltd.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 altona Diagnostics

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bio-Rad Laboratories, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Sanat Products Ltd.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Taj Pharmaceuticals Limited.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Etubics Corporation

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others





Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix





LIST OF TABLES

Table 1 Chikungunya Fever Industry Synopsis, 2017 – 2023

Table 2 Global Chikungunya Fever Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Chikungunya Fever Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 5 Global Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 6 Global Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 8 North America Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 9 North America Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 10 US Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 11 US Chikungunya Fever by Treatment, 2017 – 2023, (USD Million)

Table 12 US Chikungunya Fever by End Users, 2017 – 2023, (USD Million)

Table 13 Canada Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 Canada Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 15 Canada Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 16 South America Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 17 South America Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 18 South America Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 19 Europe Chikungunya Fever Market Market by Diagnosis, 2017 – 2023, (USD Million)

Table 20 Europe Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 21 Europe Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 22 Western Europe Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 23 Western Europe Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 24 Western Europe Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 25 Eastern Europe Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Eastern Europe Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Eastern Europe Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 28 Asia Pacific Chikungunya Fever by Diagnosis, 2017 – 2023, (USD Million)

Table 29 Asia Pacific Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 30 Asia Pacific Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)

Table 31 Middle East & Africa Chikungunya Fever Market by Diagnosis, 2017 – 2023, (USD Million)

Table 32 Middle East & Africa Chikungunya Fever Market by Treatment, 2017 – 2023, (USD Million)

Table 33 Middle East & Africa Chikungunya Fever Market by End Users, 2017 – 2023, (USD Million)





LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Chikungunya Fever Market

Figure 3 Segmentation Market Dynamics for Global Chikungunya Fever Market

Figure 4 Global Chikungunya Fever Market Share, by Diagnosis 2016

Figure 5 Global Chikungunya Fever Market Share, by Treatment 2016

Figure 6 Global Chikungunya Fever Market Share, by End Users, 2016

Figure 7 Global Chikungunya Fever Market Share, by Region, 2016

Figure 8 North America Chikungunya Fever Market Share, by Country, 2016

Figure 9 Europe Chikungunya Fever Market Share, by Country, 2016

Figure 10 Asia Pacific Chikungunya Fever Market Share, by Country, 2016

Figure 11 Middle East & Africa Chikungunya Fever Market Share, by Country, 2016

Figure 12 Global Chikungunya Fever Market: Company Share Analysis, 2016 (%)

Figure 13 Quest Diagnostics Incorporated. : Key Financials

Figure 14 Quest Diagnostics Incorporated. : Segmental Revenue

Figure 15 Quest Diagnostics Incorporated. : Geographical Revenue

Figure 16 Alere. : Key Financials

Figure 17 Alere. : Segmental Revenue

Figure 18 Alere. : Geographical Revenue

Figure 19 Genome Diagnostics Pvt. Ltd.: Key Financials

Figure 20 Genome Diagnostics Pvt. Ltd.: Segmental Revenue

Figure 21 Genome Diagnostics Pvt. Ltd..: Geographical Revenue

Figure 22 altona Diagnostics: Key Financials

Figure 23 altona Diagnostics: Segmental Revenue

Figure 24 altona Diagnostics: Geographical Revenue

Figure 25 Bio-Rad Laboratories, Inc.: Key Financials

Figure 26 Bio-Rad Laboratories, Inc.: Segmental Revenue

Figure 27 Bio-Rad Laboratories, Inc.: Geographical Revenue

Figure 28 Sanat Products Ltd.: Key Financials

Figure 29 Sanat Products Ltd.: Segmental Revenue

Figure 30 Sanat Products Ltd.: Geographical Revenue

Figure 31 Taj Pharmaceuticals Limited. : Key Financials

Figure 32 Taj Pharmaceuticals Limited. : Segmental Revenue

Figure 33 Taj Pharmaceuticals Limited. : Geographical Revenue

Figure 34 Etubics Corporation: Key Financials

Figure 35 Etubics Corporation: Segmental Revenue

Figure 36 Etubics Corporation: Geographical Revenue